Literature DB >> 30190923

Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.

Ester Simeone1, Paolo A Ascierto1.   

Abstract

Entities:  

Keywords:  anti-PD-1 antibodies; metastatic melanoma; nivolumab; pembrolizumab

Year:  2017        PMID： 30190923      PMCID： PMC6094668          DOI： 10.2217/mmt-2017-0018

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  10 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

3.  PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.

Authors:  Omar Abdel-Rahman
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

4.  IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.

Authors:  Gavin P Dunn; Kathleen C F Sheehan; Lloyd J Old; Robert D Schreiber
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

6.  Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Authors:  Daniel Y Wang; Zeynep Eroglu; Alpaslan Ozgun; Paul D Leger; Shilin Zhao; Fei Ye; Jason J Luke; Richard W Joseph; Rizwan Haq; Patrick A Ott; F Stephen Hodi; Jeffrey A Sosman; Douglas B Johnson; Elizabeth I Buchbinder
Journal:  Cancer Immunol Res       Date:  2017-04-10       Impact factor: 11.151

7.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

8.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

9.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  10 in total
  11 in total

Review 1.  Phagocytosis checkpoints as new targets for cancer immunotherapy.

Authors:  Mingye Feng; Wen Jiang; Betty Y S Kim; Cheng Cheng Zhang; Yang-Xin Fu; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2019-08-28       Impact factor: 60.716

Review 2.  Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.

Authors:  F Serra; S Barruscotti; T Dominioni; A Zuccarini; P Pedrazzoli; S Chiellino
Journal:  Curr Oncol Rep       Date:  2021-05-19       Impact factor: 5.075

3.  Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression.

Authors:  Stephanie Robu; Antonia Richter; Dario Gosmann; Christof Seidl; David Leung; Wendy Hayes; Daniel Cohen; Paul Morin; David J Donnelly; Daša Lipovšek; Samuel J Bonacorsi; Adam Smith; Katja Steiger; Christina Aulehner; Angela M Krackhardt; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2021-01-30       Impact factor: 10.057

4.  Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease.

Authors:  Julia Weiss; Michael Constantin Kirchberger; Lucie Heinzerling
Journal:  Cancer Med       Date:  2020-07-10       Impact factor: 4.452

5.  PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide.

Authors:  Tiesuo Zhao; Tian Wei; Jing Guo; Yangeng Wang; Xiangyi Shi; Sheng Guo; Xiaolong Jia; Huijie Jia; Zhiwei Feng
Journal:  Cell Death Dis       Date:  2019-02-18       Impact factor: 8.469

6.  Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway.

Authors:  Dongwei Dou; Xiaoyang Ren; Mingli Han; Xiaodong Xu; Xin Ge; Yuanting Gu; Xinxing Wang
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

7.  HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?

Authors:  Mikyung Kelly Seo; Oddbjørn Straume; Lars A Akslen; John Cairns
Journal:  Pharmacoecon Open       Date:  2020-09

Review 8.  RAGE Signaling in Melanoma Tumors.

Authors:  Olamide T Olaoba; Sultan Kadasah; Stefan W Vetter; Estelle Leclerc
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

9.  A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets.

Authors:  H D Nguyen; A Allaire; P Diamandis; M Bisaillon; M S Scott; M Richer
Journal:  BMC Med       Date:  2020-10-16       Impact factor: 8.775

Review 10.  Bacillus Calmette-Guérin Immunotherapy for Cancer.

Authors:  Fabíola Cardillo; Maiara Bonfim; Periela da Silva Vasconcelos Sousa; José Mengel; Luiz Roberto Ribeiro Castello-Branco; Rosa Teixeira Pinho
Journal:  Vaccines (Basel)       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.